pre 084 has been researched along with ampelopsin in 1 studies
Studies (pre 084) | Trials (pre 084) | Recent Studies (post-2010) (pre 084) | Studies (ampelopsin) | Trials (ampelopsin) | Recent Studies (post-2010) (ampelopsin) |
---|---|---|---|---|---|
116 | 0 | 73 | 377 | 2 | 343 |
Protein | Taxonomy | pre 084 (IC50) | ampelopsin (IC50) |
---|---|---|---|
Synaptojanin-2 | Homo sapiens (human) | 3.17 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.18 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cao, T; Guo, CH; Waddington, JL; Zhen, XC; Zheng, LT | 1 |
1 other study(ies) available for pre 084 and ampelopsin
Article | Year |
---|---|
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; DEAD-box RNA Helicases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Flavonols; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Morpholines; Oxidopamine; Parkinson Disease; Receptors, sigma; Ribonuclease III; Sigma-1 Receptor; Tamoxifen | 2020 |